Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study
From June, 1972, to December, 1976, 40 patients with FIGO (International Federation of Gynaecology and Obstetrics) Stage IIB carcinoma of the uterine cervix were entered into a prospective, double-blind, randomized study to evaluate the possible radiation-potentiating properties (i.e., improved survival) of the S-phase cell cycle-specific inhibitor of DNA synthesis, hydroxyurea. All patients were documented to be without aortic lymph node metastasis by pretherapy staging para-aortic lymphadenectomy. All 40 patients were followed up for longer than 5 years (5.2 to 9.2 years) or until death. The double-blind code was not broken until all patients had been followed up for a minimum of 2 to 5 years. Leukopenia (white blood cell count less than 2,500 mm3) was significantly increased in the patients given hydroxyurea as compared to those given placebo (P less than 0.0001). There was no statistically significant difference relative to anemia, thrombocytopenia, radiation-induced skin reaction, and radiation-induced intestinal reaction between the patients given placebo or those given hydroxyurea. Life-table survival for the patients given hydroxyurea was 94% as compared to 53% for the patients given placebo (P . 0.006). Only one (5%) patient given hydroxyurea died of cervical cancer. Of the other patients who died in the group given hydroxyurea, all were confirmed by postmortem examination to have been without recurrent cervical cancer. In contrast, 45% (nine) of the patients given placebo died of cervical cancer.
- Research Organization:
- Roswell Park Memorial Inst., Buffalo
- OSTI ID:
- 6904971
- Journal Information:
- Am. J. Obstet. Gynecol.; (United States), Vol. 147:7
- Country of Publication:
- United States
- Language:
- English
Similar Records
Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. [Radium isotopes]
Chemoradiation With Concomitant Boosts Followed by Radical Surgery in Locally Advanced Cervical Cancer: Long-term Results of the ROMA-2 Prospective Phase 2 Study
Related Subjects
HYDROXY COMPOUNDS
RADIOSENSITIVITY EFFECTS
PATIENTS
SURVIVAL TIME
UREA
BIOLOGICAL EFFECTS
UTERUS
CARCINOMAS
ANEMIAS
CHEMOTHERAPY
LEUKOPENIA
RADIOTHERAPY
TIME DEPENDENCE
AMIDES
BODY
CARBONIC ACID DERIVATIVES
DISEASES
FEMALE GENITALS
HEMIC DISEASES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
RADIOLOGY
SYMPTOMS
THERAPY
560151* - Radiation Effects on Animals- Man